Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Non-Current Deferred Tax Liability (2018 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Non-Current Deferred Tax Liability for 9 consecutive years, with $15000.0 as the latest value for Q1 2025.

  • For Q1 2025, Non-Current Deferred Tax Liability changed N/A year-over-year to $15000.0; the TTM value through Mar 2025 reached $15000.0, changed N/A, while the annual FY2022 figure was $6.3 million, 5.64% down from the prior year.
  • Non-Current Deferred Tax Liability hit $15000.0 in Q1 2025 for Sangamo Therapeutics, down from $6.4 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $7.0 million in Q2 2021 and bottomed at $15000.0 in Q1 2025.
  • Average Non-Current Deferred Tax Liability over 4 years is $5.8 million, with a median of $6.4 million recorded in 2022.
  • On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 6.61% in 2021 and fell as far as 79.12% in 2021.
  • Sangamo Therapeutics' Non-Current Deferred Tax Liability stood at $6.6 million in 2021, then dropped by 5.64% to $6.3 million in 2022, then rose by 1.63% to $6.4 million in 2023, then plummeted by 99.76% to $15000.0 in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $15000.0, $6.4 million, and $6.3 million for Q1 2025, Q1 2023, and Q4 2022 respectively.